OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Michael G. Ison, Debra F. Weinstein, Marta Dobryanska, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 11
Michael G. Ison, Debra F. Weinstein, Marta Dobryanska, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 11
Showing 11 citing articles:
An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2
Daniele Focosi, Massimo Franchini, Arturo Casadevall, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 999-1006
Closed Access | Times Cited: 9
Daniele Focosi, Massimo Franchini, Arturo Casadevall, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 999-1006
Closed Access | Times Cited: 9
A generalized framework to identify SARS-CoV-2 broadly neutralizing antibodies
Fanchong Jian, Anna Z. Wec, Leilei Feng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Fanchong Jian, Anna Z. Wec, Leilei Feng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Emerging anti-spike monoclonal antibodies against SARS-CoV-2
Eloy E. Ordaya, Raymund R. Razonable
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 191-201
Closed Access | Times Cited: 4
Eloy E. Ordaya, Raymund R. Razonable
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 191-201
Closed Access | Times Cited: 4
Synthetic coevolution reveals adaptive mutational trajectories of neutralizing antibodies and SARS-CoV-2
Roy A. Ehling, Mason Minot, Max D. Overath, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Roy A. Ehling, Mason Minot, Max D. Overath, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 2
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 2
Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19
Peter Schmidt, Yong Li, Myra Popejoy
New England Journal of Medicine (2024) Vol. 391, Iss. 19, pp. 1860-1862
Open Access | Times Cited: 2
Peter Schmidt, Yong Li, Myra Popejoy
New England Journal of Medicine (2024) Vol. 391, Iss. 19, pp. 1860-1862
Open Access | Times Cited: 2
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients
Sabina Herrera, José María Aguado, Francisco Javier Candel, et al.
Transplantation Reviews (2023) Vol. 37, Iss. 4, pp. 100788-100788
Closed Access | Times Cited: 6
Sabina Herrera, José María Aguado, Francisco Javier Candel, et al.
Transplantation Reviews (2023) Vol. 37, Iss. 4, pp. 100788-100788
Closed Access | Times Cited: 6
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis
Adarsh Bhimraj, Yngve Falck–Ytter, A. Y. Kim, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 1
Adarsh Bhimraj, Yngve Falck–Ytter, A. Y. Kim, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 1
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial
Cameron R. Wolfe, Jonathan Cohen, Kathryn Mahoney, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Cameron R. Wolfe, Jonathan Cohen, Kathryn Mahoney, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Vaccination in Adults with Diabetes Mellitus: A Position Statement of the Diabetes Mellitus Study Group of the Portuguese Society of Endocrinology, Diabetes, and Metabolism
Pedro O. S. Vaz de Melo, Paula Freitas, Raquel Carvalho, et al.
Deleted Journal (2024), pp. 1-11
Open Access
Pedro O. S. Vaz de Melo, Paula Freitas, Raquel Carvalho, et al.
Deleted Journal (2024), pp. 1-11
Open Access
